Fibrocell Science, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.20%177.870.7%$1343.04m
MRKMerck & Co., Inc. 0.46%91.590.7%$1173.21m
PFEPfizer Inc. -1.32%51.740.9%$1099.03m
LLYEli Lilly & Co. -1.12%320.611.1%$1034.00m
BMYBristol-Myers Squibb Co. -0.97%76.251.0%$998.04m
ABBVAbbVie, Inc. -0.76%152.001.9%$951.47m
AZNAstraZeneca Plc -1.02%65.401.0%$437.00m
SGENSeagen Inc. 0.81%178.385.7%$318.46m
TPTXTurning Point Therapeutics, Inc. -0.12%75.160.0%$287.74m
GSKGSK Plc -0.24%43.430.2%$275.82m
HZNPHorizon Therapeutics Plc 0.78%80.385.4%$163.06m
NVSNovartis AG -0.99%83.690.2%$162.94m
MRTXMirati Therapeutics, Inc. 3.81%69.691.6%$152.30m
ALNYAlnylam Pharmaceuticals, Inc. 1.31%147.768.1%$142.36m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.15%145.490.0%$142.11m

Company Profile

Fibrocell Science, Inc., is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. They have a robust pipeline and clinical programs based on the autologous fibroblast cell. They believe their aesthetic indication is a beachhead for higher value indications. They have a strong base of knowledge and expertise in cell based product development, manufacturing and seeking regulatory approvals. Their focus is to enter clinical programs to treat medical conditions that have an unmet need, helping patients and creating more value per cell.